Francisca Molina-Escribano

Dr. Francisca Molina-Escribano

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Hypertension
Verified
Journal Article
Closed access
JDJuan A. Divison-Garrote
Juan A. Divison-Garrote
JCJulio Antonio Carbayo Carbayo-Herencia
Julio Antonio Carbayo Carbayo-Herencia
MSMarta Simarro-Rueda
Marta Simarro-Rueda
FMFrancisca Molina-Escribano
Francisca Molina-Escribano
Carlos EscobarCarlos Escobar
Carlos Escobar
JBJosé R Banegas
José R Banegas
BACKGROUND: Guidelines recommend pharmacological treatment for systolic blood pressure (SBP) of 130 to 139 mm Hg in secondary prevention. However, uncertainty persists in primary prevention in low cardiovascular risk patients (CVR). METHODS: Cohort study representative of the general population of Albacete/Southeast Spain. We examined 1029 participants with untreated blood pressure and free of cardiovascular disease, followed-up during 1992 to 2019. Cox regression modeled the association of SBP with cardiovascular morbidity and mortality (outcome-1) and cardiovascular morbidity and all-cause mortality (outcome-2). RESULTS: Participants’ mean age was 44.8 years (53.8%, women; 77.1% at low-CVR); 20.3% had SBP 120 to 129; 13.0% 130 to 139 at low-CVR and 3.4% at high-CVR; and 27.4% ≥140 mm Hg. After a 25.7-year median follow-up, 218 outcome-1 and 302 outcome-2 cases occurred. Unadjusted hazard ratios of outcome-1 for these increasing SBP categories (versus <120) were 2.72, 2.27, 11.54, and 7.52, respectively; and 2.69, 2.32, 10.55, and 7.34 for outcome-2 (all P <0.01). After adjustment for other risk factors, hazard ratio (95% CI) of outcome-1 were 1.49 (0.91–2.44), 1.65 (0.94–2.91, P =0.08), 1.36 (0.72–2.57), and 1.82 (1.15–2.88), respectively, and 1.39 (0.91–2.11), 1.69 (1.05–2.73), 1.09 (0.63–1.88), and 1.64 (1.11–2.41) for outcome-2. Compared with 130 to 139 at low-CVR, hazard ratio for 130 to 139 at high-CVR was 4.85 for outcome-1 ( P <0.001) and 4.43 for outcome-2 ( P <0.001). CONCLUSIONS: In this primary prevention population of relatively young average age, untreated SBP of 130 to 139 mm Hg at low-CVR had long-term prognostic value and might benefit from stricter SBP targets. High-CVR patients had nonsignificant higher risk (limited sample size) but 4-fold greater risk when compared with low-CVR. Overall, results indicate the importance of risk stratification, supporting risk-based decision-making.

1 June 2008 in Revista Clínica de Medicina de Familia
Verified
Journal Article
Open access
PDF file
FMFrancisca Molina-Escribano
Francisca Molina-Escribano
EMEncarna Castaño Moreno
Encarna Castaño Moreno
JOJavier Massó Orozco
Javier Massó Orozco

21 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JCJulio Antonio Carbayo Carbayo-Herencia
Julio Antonio Carbayo Carbayo-Herencia
LRLuis Miguel Artigao Rodenas
Luis Miguel Artigao Rodenas
MSMarta Simarro-Rueda
Marta Simarro-Rueda
FMFrancisca Molina-Escribano
Francisca Molina-Escribano
FNFrancisca Navarro-Blazquez
Francisca Navarro-Blazquez
JDJuan Antonio Divisón-Garrote
Juan Antonio Divisón-Garrote
Objectives: This study evaluated the association of resting heart rate (RHR) with major adverse cardiovascular events (MACEs) and all-cause mortality among adults without prior cardiovascular disease, stratified by baseline burden of cardiovascular risk factors (CVRFs). Methods: This was a prospective cohort study in a random sample of the general population aged ≥18 years in southeastern Spain. RHR was measured using an electrocardiogram. CVRFs (sedentary or light-to-moderate physical activity, body-mass index ≥ 25 kg/m2, non-HDL cholesterol ≥ 130 mg/dL, diabetes, hypertension, and smoking) were grouped in three clusters based on whether each subject has 0–2, 3, or ≥4 factors. During a mean 21.5-year follow-up, MACEs were collected and classified as all-cause mortality (outcome-1, n = 193 events) and combined cardiovascular morbidity and mortality (outcome-2, n = 291 events). Cox regression models were adjusted for multiple confounders. Results: The mean age of the participants (n = 1169) was 47.4 years (55.8% women). For every 10 bpm increase in RHR, the fully adjusted hazard ratio was 1.15 (95% CI: 1.03–1.28) for outcome-1 and 1.09 (1.00–1.20) for outcome-2. In the cluster with three CVRFs, the fully adjusted hazard ratios per 10 bpm RHR increase were 1.18 (95% CI 1.04–1.36) for outcome-1 and 1.15 (1.03–1.27) for outcome-2. In the clusters with 0–2 and ≥4 CVRFs, there were no statistically significant differences. Conclusions: RHR was independently associated with both cardiovascular events and all-cause mortality in the 3 CVRF cluster (intermediate cluster in terms of the burden of CVRFs), whose prognostic value may be clinically meaningful. These results highlight the importance of RHR and the comprehensive assessment of CVRFs in the primary prevention setting.